No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CGEN Compugen
- 1.9100
- -0.0500-2.55%
Trading Jun 18 12:58 ET
171.00MMarket Cap-10611P/E (TTM)
1.9800High1.8500Low238.03KVolume1.9500Open1.9600Pre Close454.90KTurnover0.28%Turnover RatioLossP/E (Static)89.53MShares3.030152wk High2.86P/B161.77MFloat Cap0.530052wk Low--Dividend TTM84.70MShs Float19.9000Historical High--Div YieldTTM6.63%Amplitude0.3400Historical Low1.9110Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Express News | Compugen To Receive $5M Milestone Payment From AstraZeneca Following Dosing Of First Patient In Second Phase 3 Trial Of Rilvegostomig
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 118.58% Truist Securities $5 → $4 Maintains Buy 03/08/2024 173.22% Truist Securities $4 → $5 Ma
Comments
$Compugen(CGEN.US$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen(CGEN.US$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen(CGEN.US$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg